1. A monoclonal antibody targeting the C-terminal subunit of Mucin1 was produced that binds specifically to Mucin1 overexpressed in breast cancer cells. 2. In mouse models, the antibody localized to tumors derived from three breast cancer cell lines and showed prolonged retention in tumors compared to normal IgG. 3. The antibody inhibited the proliferation of breast cancer cells overexpressing Mucin1 in vitro, suggesting it may be a candidate for breast cancer therapy.